Fairvalue-Calculator Fairvalue-Calculator
EN DE

Greenyn Biotechnology Co (6846) Fair Value & Analysis

Healthcare · TW · Market cap 1.8B TWD

Price67.00 TWD
Fair Value95.85 TWD
Upside+43.1%
Quality95/100
Evidence: High Range 67.10 TWD – 124.61 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Greenyn Biotechnology Co (6846) currently trades at 67.00 TWD, while our model-based Fair Value estimate is 95.85 TWD — implying the stock looks roughly 43.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Greenyn Biotechnology Co (6846) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 95.85 TWD versus a price of 67.00 TWD — about +43% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6846?
Our 21-model fair value for Greenyn Biotechnology Co is 95.85 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 67.00 TWD.
What is the quality score of 6846?
Greenyn Biotechnology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.